All Articles

With a fresh $200M at a $1B valuation, Standard Bots is scaling its AI-native, 'teach-by-demonstration' robots to challenge global rivals and redefine the U.S. factory floor.

As staffing crises cripple New England hospitals, York Hospital's partnership with ShiftMed offers a tech-driven fix. But is the gig model the ultimate cure?

The firm is betting that flexibility is the key to unlocking the next wave of SaaS revenue, challenging the rigid models that have defined embedded payments.

Quantified's new platform promises a future of continuous, compliant sales coaching. It's not just training; it's a bid to become the system of record.

A new wave of AI promises to redesign health plan operations, not just automate them. We look at the systems aiming to connect a fragmented industry.

A new AssetMark study reveals many advisors' gains are just market lift. The real winners are building systems for hiring, referrals, and accountability.

Rain's new Agent Control Layer gives businesses the power to set precise spending rules for AI agents, unlocking a new era of secure, autonomous commerce.

With over half a billion in funding, Beacon is buying the small, essential businesses we rely on and supercharging them with a radical AI-native platform.

As new rules force firms to report their digital carbon footprint, a new solution from Sweep and AWS promises audit-ready data directly from the cloud.

New data reveals a grim reality: Texas rural roads are nearly three times deadlier than city streets, exposing a deep infrastructure and safety crisis.

With a new hybrid, premium tech, and a higher price, Kia's redesigned Seltos isn't just an update; it's a strategic move to redefine value in a crowded segment.

Matisse Pharmaceuticals' new sepsis drug just got a major boost from the FDA. But the real story is the invisible infrastructure—both biological and regulatory—it aims to master.

With a massive discount and an activist investor on its tail, Highland Opportunities Fund doubles down on a buyback strategy. Can $100M succeed where a previous program struggled?

The tech-first insurer enters the Peace Garden State, betting its AI-powered app, low prices, and B-Corp mission can reshape a traditional market.

Enveric Biosciences heads to a key UBS investor day to pitch its non-hallucinogenic antidepressant, EB-003. Can it secure the capital needed to revolutionize CNS?

A Maryland firm just got funding for 'universal' stem cells. This isn't just science; it's the blueprint for off-the-shelf cures and a new era of medicine.

A Houston private equity firm just sold off its Permian Basin assets for an undisclosed sum, but the real story is the blueprint it reveals for profiting from a frenzied M&A market.

As Acorn Energy faces investors, a recent dip in hardware revenue highlights its ongoing focus on high-margin services and advanced IoT, expanding its capacity to secure the grid.

A Phoenix cleaning service won a top award not just for its results, but for a radical business model: honesty. Here's how it's changing the game.

As officer assaults hit a decade high, a new bill in Ohio seeks life without parole for cop killers, igniting a fierce debate on deterrence and justice.